Myriad Genetics (MYGN) Tops Q1 EPS by 6c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.17 -1.86%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.
Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015 revenue of $750-770 million, versus the consensus of $758.3 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
